Sun Pharmaceutical (SUNPHARMA.NS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $47.03B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IN | CEO | Kirti Ganorkar |
| IPO Date | 1996-01-01 | CAGR | 20.4% |
| Employees | 47,000 | Website | www.sunpharma.com |
| Div. Yield | 0.79% | Payout Ratio | 11% |
| Buy Back Yield | — | Total Yield | 0.79% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $41.27B | P/E | 36.42 | Forward P/E | 29.16 | PEG | 1.4 |
| P/S | 8.35 | P/B | 5.84 | P/CF | 102.16 | P/FCF | 203.91 |
| Sales | $6.06B | Sales 1Y | 11.19% | Sales 3Y | 33.21% | Sales 5Y | 74.52% |
| EPS | $0.54 | EPS 1Y | 4.87% | EPS 3Y | 35.52% | EPS 5Y | 294.39% |
| Sales QoQ | -5.86% | EPS QoQ | -19.52% | Sales QoQ Avg | 3.19% | EPS QoQ Avg | 7.72% |
| Gross Margin | 55.7% | Operating Margin | 23.18% | Profit Margin | 19.64% | ROCE | 15.73% |
| ROA | 11% | ROE | 15% | Altman Z Score | 13.69 | Piotroski Score | 3 |
| Current Ratio | 2.82 | Quick Ratio | 2.31 | Cash Ratio | 0.51 | Op. CF Ratio | — |
| Debt/Equity | 0.06 | Debt/Assets | 0.04 | Lt Debt/Equity | 0 | Lt Debt/Cap. | 0 |
| Intrst Cov. | 39.99 | Inventory Turnover | 2.25 | Asset Turnover | 0.54 | Receivables Turnover | 3.76 |
| Enterprise Value | $41.27B | P/E Ratio | 36.42 |
| Forward P/E | 29.16 | PEG Ratio | 1.4 |
| P/S Ratio | 8.35 | P/B Ratio | 5.84 |
| P/CF Ratio | 102.16 | P/FCF Ratio | 203.91 |
| EPS | $0.54 | EPS Growth 1Y | 4.87% |
| EPS Growth 3Y | 35.52% | EPS Growth 5Y | 294.39% |
| Revenue Growth 1Y | 11.19% | Gross Margin | 0.56% |
| Operating Margin | 0.23% | Profit Margin | 0.2% |
| ROE | 0.15% | ROA | 0.11% |
| ROCE | 0.16% | Current Ratio | 2.82 |
| Quick Ratio | 2.31 | Cash Ratio | 0.51 |
| Debt/Equity | 0.06 | Interest Coverage | 39.99 |
| Altman Z Score | 13.69 | Piotroski Score | 3 |
Sun Pharmaceutical (SUNPHARMA.NS) valuation & financials
Sun Pharmaceutical (SUNPHARMA.NS) has a market capitalization of 47.03B INR and trades at a price-to-earnings ratio of 36.4. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Sun Pharmaceutical's revenue grew +11.2% over the last year.
Sun Pharmaceutical's next earnings report is scheduled for November 3, 2026; analysts estimate EPS of 0.13 INR. Check the earnings calendar to see all companies reporting this week.
Sun Pharmaceutical (SUNPHARMA.NS) — frequently asked questions
When does Sun Pharmaceutical (SUNPHARMA.NS) report earnings next?
Sun Pharmaceutical is expected to report earnings on November 3, 2026. Analysts estimate EPS of 0.13 INR.
What is Sun Pharmaceutical's market cap?
Sun Pharmaceutical (SUNPHARMA.NS) has a market capitalization of 47.03B INR.
What is SUNPHARMA.NS's P/E ratio?
Sun Pharmaceutical trades at a price-to-earnings ratio of 36.4, with trailing twelve-month EPS of 0.54 INR.
How fast is Sun Pharmaceutical growing?
Sun Pharmaceutical's revenue grew +11.2% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)